Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
University of Michigan Rogel Cancer Center
With
OBJECTIVES: * Determine the maximum tolerated dose (MTD) of curcumin as a chemopreventive agent of colon cancer in healthy subjects. * Determine if tolerable doses of this agent in uniformly milled formulation capsules are bioavailable in these subjects. * Determine the pharmacokinetics of this agent and two metabolites at the MTD and next lower escalated dose in these subjects. OUTLINE: This is a dose escalation study followed by a pharmacokinetic study. Patients receive a single oral dose of curcumin followed by a standard fatty meal. Cohorts of 3-6 patients receive escalating doses of curcumin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicities. Once the MTD is determined, additional patients are accrued to receive curcumin in the pharmacokinetic phase of the study. Patients are followed at 24, 36, 48, and 72 hours. PROJECTED ACCRUAL: A total of 3-24 patients will be accrued for the dose escalation phase and then 12 additional patients will be accrued for the pharmacokinetic phase of this study within 3 months.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted